Lung Cancer News

The development of more effective treatments — including personalized therapies — have dramatically improved outcomes for children and adolescents with cancer, according to American Association for Cancer Research’s Cancer Progress Report.

Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.

Ivonescimab significantly improved PFS compared with pembrolizumab as first-line treatment of PD-L1-positive advanced non-small cell lung cancer, according to results of the HARMONi-2 trial.

Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.

Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers persist, according to survey results.

Patients with central airway obstruction are often treated by multiple clinicians from different specialties, leading to varied management of the patients, according to a press release.

Neoadjuvant atezolizumab prior to chemoradiation therapy exhibited promising activity for patients with unresectable stage III non-small cell lung cancer, according to results of a nonrandomized phase 2 study.

Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.